Results 11 to 20 of about 52,949 (209)

Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. [PDF]

PLoS ONE, 2015
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, these patients eventually develop resistance to EGFR-TKI.
Mei-Chuan Tang, Mei-Yi Wu, Ming-Hung Hwang, Ya-Ting Chang, Hui-Ju Huang, Anya Maan-Yuh Lin, James Chih-Hsin Yang   +6 more
doaj   +3 more sources

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer [PDF]

Contemporary Oncology, 2016
Aim of the study : Many studies have shown that interferon-α(IFN-α) enhances the antiproliferative effect of gefitinib in some solid tumours. We aimed to determine the effect of combining IFN-αwith gefitinib in human non-small cell lung cancer (NSCLC ...
Chi Pan, Shanshan Weng, Yin Duan, Ling Ding, Suzhan Zhang, Jianjin Huang   +5 more
doaj   +2 more sources

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line

Cancer Medicine, 2020
We aimed to explore the molecular substrate underlying EGFR‐TKI resistance and investigate the effects of N‐acetylcysteine (NAC) on reversing EGFR‐TKI resistance.
Jun Li, Xiao‐Hui Wang, Jing Hu, Meng Shi, Lu Zhang, Hong Chen   +5 more
doaj   +2 more sources

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib

Case Reports in Pulmonology, 2011
A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic ...
Tatsuya Nagano, Yoshikazu Kotani, Kazuyuki Kobayashi, Masahiro Katsurada, Yukihisa Hatakeyama, Suya Hori, Daisuke Tamura, Daisuke Kasai, Yasuhiro Funada, Yoshihiro Nishimura   +9 more
doaj   +2 more sources

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

Frontiers in Pharmacology, 2021
Drug resistance can notably restrict clinical applications of gefitinib that is a commonly used EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC).
Yuhong Jiang, Xin Zhuo, Xiujuan Fu, Yue Wu, Canquan Mao   +4 more
doaj   +1 more source

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells

Respiratory Research, 2021
Background Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been used as first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, during treatment, cancer cells often develop resistance to gefitinib, the
Shaojia Wang, Chao Liu, Qing Lei, Zhengwei Wu, Xiangshuai Miao, Debing Zhu, Xu Yang, Na Li, Mingwei Tang, Yan Chen, Weiwei Wang   +10 more
doaj   +1 more source

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

BMC Pulmonary Medicine, 2022
Background Gefitinib is recommended as a first-line treatment option for elderly patients with non-small cell lung cancer (NSCLC). Because no pharmacokinetics of gefitinib have been examined, we prospectively assessed the pharmacokinetics of gefitinib in
Yuta Nio, Hiroo Ishida, Natsumi Matsumoto, Sojiro Kusumoto, Yutaro Kubota, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita   +7 more
doaj   +1 more source

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. [PDF]

PLoS ONE, 2011
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with L858R or exon 19 deletion mutations in epidermal growth factor receptor (EGFR) have good responses to the tyrosine kinase inhibitor (TKI), gefitinib.
Jen-Yi Lee, Yee-Ming Lee, Gee-Chen Chang, Sung-Liang Yu, Wan-Yu Hsieh, Jeremy J W Chen, Huei-Wen Chen, Pan-Chyr Yang   +7 more
doaj   +1 more source

Gefitinib and Sonidegib [PDF]

Hospital Pharmacy, 2015
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Corey J, Medler, J Aubrey, Waddell, Dominic A, Solimando   +2 more
openaire   +2 more sources

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. [PDF]

PLoS ONE, 2013
Gefitinib (Iressa(®), ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. We report on an early cellular response to gefitinib that involves induction of functional autophagic flux in phenotypically ...
Wieslawa H Dragowska, Sherry A Weppler, Jun Chih Wang, Ling Yan Wong, Anita I Kapanen, Jenna S Rawji, Corinna Warburton, Mohammed A Qadir, Elizabeth Donohue, Michel Roberge, Sharon M Gorski, Karen A Gelmon, Marcel B Bally   +12 more
doaj   +1 more source